Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Dosimetric Comparison of Brain Sparing Between HyperArc and GammaKnife for Single to Triple Brain Metastases

YOSHIHIRO UEDA, KANJI MORI, SHINGO OHIRA, KAZUO TARUTANI, NAOYUKI KANAYAMA, AYAKO OKAMURA and KOJI KONISHI
Anticancer Research April 2025, 45 (4) 1631-1641; DOI: https://doi.org/10.21873/anticanres.17544
YOSHIHIRO UEDA
1Department of Radiation Oncology, Osaka International Cancer Institute, Osaka, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: uedetu@gmail.com
KANJI MORI
2Department of Neurosurgery, Kansai Rosai Hospital, Amagasaki, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SHINGO OHIRA
1Department of Radiation Oncology, Osaka International Cancer Institute, Osaka, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KAZUO TARUTANI
3Department of Radiation Oncology, Kansai Rosai Hospital, Amagasaki, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
NAOYUKI KANAYAMA
1Department of Radiation Oncology, Osaka International Cancer Institute, Osaka, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
AYAKO OKAMURA
3Department of Radiation Oncology, Kansai Rosai Hospital, Amagasaki, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KOJI KONISHI
1Department of Radiation Oncology, Osaka International Cancer Institute, Osaka, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background/Aim: A novel linac-bases radiosurgery (SRS) system, HyperArc, applied to the non-coplanar volume-modulated arc therapy (VMAT) technique, was developed and released in clinical practice. The aim of the study was to evaluate the dosimetric performance of brain sparing in single-target to three-target cases, for two types of SRS systems: GammaKnife and HyperArc.

Patients and Methods: A total of 83 patients treated with GammaKnife SRS (35 with single, 24 with double, and 24 with triple metastases) were retrospectively analyzed. Treatment plans were recalculated using HyperArc. Dosimetric parameters, including conformity index (CI), gradient index (GI), and brain volume receiving 2-20 Gy (V2-V20), were compared between the two systems.

Results: No significant difference in D99 of the planning target volume (PTV) was observed between GammaKnife and HyperArc. HyperArc exhibited superior CI100, with values approaching 1.0. V4-V20 for the whole brain minus PTV were significantly lower for HyperArc than GammaKnife. In single-target cases, GI was significantly lower for HyperArc, while in triple-target cases, it was higher. V12 volumes for HyperArc were comparable to those for GammaKnife, even in cases with volumes <1.0 cm3.

Conclusion: HyperArc demonstrated dosimetric performance comparable to or better than GammaKnife in brain sparing for single-to-triple metastases. These findings support HyperArc as an effective alternative for SRS planning.

Keywords:
  • HyperArc
  • GammaKnife
  • brain sparing
  • brain metastasis
  • Received February 17, 2025.
  • Revision received March 6, 2025.
  • Accepted March 7, 2025.
  • Copyright © 2025 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
View Full Text

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.

patientACCESS

patientACCESS - Patients desiring access to articles
PreviousNext
Back to top

In this issue

Anticancer Research: 45 (4)
Anticancer Research
Vol. 45, Issue 4
April 2025
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Dosimetric Comparison of Brain Sparing Between HyperArc and GammaKnife for Single to Triple Brain Metastases
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
10 + 3 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Dosimetric Comparison of Brain Sparing Between HyperArc and GammaKnife for Single to Triple Brain Metastases
YOSHIHIRO UEDA, KANJI MORI, SHINGO OHIRA, KAZUO TARUTANI, NAOYUKI KANAYAMA, AYAKO OKAMURA, KOJI KONISHI
Anticancer Research Apr 2025, 45 (4) 1631-1641; DOI: 10.21873/anticanres.17544

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Dosimetric Comparison of Brain Sparing Between HyperArc and GammaKnife for Single to Triple Brain Metastases
YOSHIHIRO UEDA, KANJI MORI, SHINGO OHIRA, KAZUO TARUTANI, NAOYUKI KANAYAMA, AYAKO OKAMURA, KOJI KONISHI
Anticancer Research Apr 2025, 45 (4) 1631-1641; DOI: 10.21873/anticanres.17544
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Patients and Methods
    • Results
    • Discussion
    • Conclusion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Prediction of Severe Anemia and Neutropenia Induced by Abemaciclib in Patients With Breast Cancer
  • Impact of Nivolumab Plus Chemotherapy on Conversion Therapy in Clinical Stage IVB HER2-negative Gastric Cancer
  • Treatment Outcomes After Progression With Enfortumab Vedotin in Patients With Advanced Urothelial Carcinoma
Show more Clinical Studies

Similar Articles

Keywords

  • HyperArc
  • GammaKnife
  • brain sparing
  • brain metastasis
Anticancer Research

© 2025 Anticancer Research

Powered by HighWire